Lyra Therapeutics, Inc.

NasdaqGM:LYRA Stock Report

Mkt Cap: US$85.0m

Lyra Therapeutics Future Growth

How is Lyra Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


9.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGM:LYRA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202512-84-86-742
12/31/2024N/A-75-75-712
12/31/20230-63-68-624
9/30/20222-55-44-43N/A
6/30/20221-51-44-42N/A
3/31/20221-48-32-30N/A
12/31/20210-44-29-26N/A
9/30/20210-37-24-20N/A
6/30/2021N/A-32-17-14N/A
3/31/2021N/A-26-28-25N/A
12/31/2020N/A-22-23-21N/A
9/30/2020N/A-20-20-19N/A
6/30/2020N/A-18-19-19N/A
3/31/2020N/A-17-15-15N/A
12/31/2019N/A-17-14-14N/A
12/31/20181-6-7-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LYRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LYRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LYRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LYRA's revenue (71% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: LYRA's revenue (71% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LYRA's Return on Equity is forecast to be high in 3 years time


Discover growth companies